Advertisement

Influence of Kidney Function on Risk of Hemorrhage Among Patients Taking Warfarin: A Cohort Study

Published:November 19, 2012DOI:https://doi.org/10.1053/j.ajkd.2012.09.012
      CKD affects more than 26 million Americans, of whom 15.5 million have stage 3 CKD (eGFR, 30-<60 mL/min/1.73 m2).
      • Coresh J.
      • Selvin E.
      • Stevens L.A.
      • et al.
      Prevalence of chronic kidney disease in the United States.
      This broad categorization fails to recognize important differences between patients with stage 3a (eGFR, 45-59 mL/min/1.73 m2) and 3b (eGFR, 30-44 mL/min/1.73 m2) CKD.
      • Huang S.M.
      • Temple R.
      • Xiao S.
      • Zhang L.
      • Lesko L.J.
      When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
      • Levey A.S.
      • de Jong P.E.
      • Coresh J.
      • et al.
      The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
      Compared with warfarin users with eGFR ≥60 mL/min/1.73 m2, those with stage 3 CKD have a similar risk of hemorrhage, whereas those with stages 4/5 (eGFR <30 mL/min/1.73 m2) have a higher risk.
      • Limdi N.A.
      • Beasley T.M.
      • Baird M.F.
      • et al.
      Kidney function influences warfarin responsiveness and hemorrhagic complications.
      Here, we evaluate whether the risk of warfarin-related hemorrhage differs between patients with stage 3a and 3b CKD.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
        • Huang S.M.
        • Temple R.
        • Xiao S.
        • Zhang L.
        • Lesko L.J.
        When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
        Clin Pharmacol Ther. 2009; 86: 475-479
        • Levey A.S.
        • de Jong P.E.
        • Coresh J.
        • et al.
        The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
        Kidney Int. 2011; 80: 17-28
        • Limdi N.A.
        • Beasley T.M.
        • Baird M.F.
        • et al.
        Kidney function influences warfarin responsiveness and hemorrhagic complications.
        J Am Soc Nephrol. 2009; 20: 912-921
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Fihn S.D.
        • McDonell M.
        • Martin D.
        • et al.
        Risk factors for complications of chronic anticoagulation.
        Ann Intern Med. 1993; 118: 511-520
        • Therneau T.M.
        • Grambsch P.M.
        Multiple events per subject.
        in: Therneau T.M. Grambsch P.M. Modeling Survival Data: Extending the Cox Model (Statistics for Biology and Health). 1st ed. Springer-Verlag, New York, NY2001: 169-229
        • Limdi N.A.
        • McGwin G.
        • Goldstein J.A.
        • et al.
        Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
        Clin Pharmacol Ther. 2008; 83: 312-321